Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$885.55 USD

885.55
1,951,041

-5.52 (-0.62%)

Updated Oct 3, 2024 04:00 PM ET

After-Market: $885.35 -0.20 (-0.02%) 4:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 13% (32 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Lilly (LLY) Gets FDA Approval for Higher Doses of Trulicity

Lilly's (LLY) higher doses of Trulicity led to superior reductions in blood glucose level and weight in type II diabetes patients compared to the currently available dose.

Eli Lilly (LLY) Stock Moves -0.35%: What You Should Know

In the latest trading session, Eli Lilly (LLY) closed at $149.02, marking a -0.35% move from the previous day.

AstraZeneca's Farxiga Betters Survival in Renal Outcome Study

AstraZeneca's (AZN) Farxiga significantly reduces the risk of kidney failure and cardiovascular or death in patients with chronic kidney disease.

Why Eli Lilly (LLY) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.

Why Is Lilly (LLY) Down 3.7% Since Last Earnings Report?

Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Radhika Pujara headshot

Workday (WDAY) Tops on Q2 Earnings & Revenues, Stock Rises

Workday's (WDAY) fiscal second-quarter results benefit from a high demand for its cloud-based HCM and financial management solutions, and synergies from the Scout RFP acquisition.

Kinjel Shah headshot

Pharma Stock Roundup: SNY, JNJ Acquisition Deals, FDA Approvals

J&J (JNJ) proposes to buy Momenta Pharmaceuticals while Sanofi (SNY) offers to buy Principia Biopharma

United Therapeutics Announces FDA Acceptance of Tyvaso sNDA

United Therapeutics' (UTHR) INCREASE study evaluated Tyvaso in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Kinjel Shah headshot

Pharma Stock Roundup: FDA Approval for Roche's SMA Drug & Other Updates

Teaser: FDA approves Roche's (RHHBY) new SMA drug, Evrysdi (risdiplam).

Kinjel Shah headshot

Large-Cap Pharma Industry Outlook Dull Amid Coronavirus Woes

The Zacks Large-Cap Pharmaceuticals industry ranks in the bottom 26% of more than 250 Zacks industries.

Radius' (RDUS) Q2 Earnings Miss Estimates, Sales Surpass

Radius (RDUS) reports a wider-than-expected loss but beats sales estimates in the second quarter.

Ritujay Ghosh headshot

5 Stocks in the Spotlight on Trump's Coronavirus Vaccine Optimism

Millions are pinning their hopes on a handful of drugmakers, which are into the final phases of their vaccine trial.

Sweta Killa headshot

Pharma ETFs Soar on Robust Q2 Earnings

Total earnings of 66.4% of the healthcare market capitalization that has reported so far are up 4.4% on revenue growth of 4%.

Kinjel Shah headshot

Pharma Stock Roundup: ABBV, MRK Q2 Earnings & Coronavirus Updates in Focus

Sanofi (SNY)/Glaxo (GSK) and J&J (JNJ) sign deals with U.S. government for coronavirus vaccine candidate. Several drugmakers announce second-quarter results.

The Zacks Analyst Blog Highlights: Apple, Mastercard, Eli Lilly, PetroChina and Anheuser-Busch InBev

The Zacks Analyst Blog Highlights: Apple, Mastercard, Eli Lilly, PetroChina and Anheuser-Busch InBev

Novo Nordisk's (NVO) Q2 Earnings Beat Estimates, Sales Miss

Novo Nordisk's (NVO) earnings surpass estimates but revenues miss the same in the second quarter of 2020.

Sheraz Mian headshot

Top Stock Reports for Apple, Mastercard & Eli Lilly

Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Mastercard (MA) and Eli Lilly (LLY).

The Zacks Analyst Blog Highlights: Eli Lilly, Moderna, Pfizer, Sanofi, GlaxoSmithKline and BioNTech

The Zacks Analyst Blog Highlights: Eli Lilly, Moderna, Pfizer, Sanofi, GlaxoSmithKline and BioNTech

Benjamin Rains headshot

3 Diverse Large-Cap Stocks to Buy Now to Boost Your Long-Term Portfolio

Investors should consider adding a few large-cap names that are prepared to grow for years to come. These three stocks also pay dividends and provide exposure to three very different and vital industries...

Sweta Killa headshot

5 Growth ETFs & Stocks to Ride the Market Rally

Growth investing has taken the lead over value and is likely to stay given a slew of reasons.

Incyte (INCY) Beats on Q2 Earnings and Sales on Strong Jakafi

Incyte (INCY) easily surpasses earnings and sales expectations in the second quarter as lead drug, Jakafi, reports strong growth.

Ritujay Ghosh headshot

Pharma Stocks in Focus on Late-Stage Coronavirus Vaccine Trials

Hopes of a vaccine have once again started rising with a number of companies now entering the final phase of their trials.

Kinjel Shah headshot

Pharma Stock Roundup: Q2 Earnings & J&J and PFE's Coronavirus Updates in Focus

Pfizer's (PFE) coronavirus vaccine candidate enters phase III. Several drugmakers announce second-quarter results.